Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population

Cancer Genetics and Cytogenetics

Volumn 185, Issue 2, 2008, Pages 78-85

  Sobti, R C ^a   Gupta, L ^a   Singh, S K ^b   Seth, A ^c   Kaur, P ^a   Thakur, H ^a  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 17; ESTROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE 2; STEROID HORMONE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; GENE FUNCTION; GENE INTERACTION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT; STEROID METABOLISM; STEROIDOGENESIS;

AGED; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; EPISTASIS, GENETIC; ESTROGEN RECEPTOR ALPHA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 49649087629     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.04.022     Document Type: Article

References (37)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54 (1993) 594-606
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer Statistics. CA Cancer J Clin 57 (2007) 43-66
3. Pal S.K., and Mittal B. Improving cancer care in India: prospects and challenges. Asian Pacific J Cancer Prevent 5 (2004) 226-228
4. Sunny L., Yeole B.B., Kurkure A.P., Hakama M., Shiri R., Mathews S., Shastri N.G., and Adwani S.H. Cumulative risks and trends in prostate cancer incidence in Mumbai India. Asian Pecific J. Cancer Prev 5 (2004) 401-405
5. Pal S. Neoadjuvent chemotherapy in the management of respectable oesophageal cancer. Nat Med J India 15 (2002) 278-280
6. Hsing A.W., and Chokkalingam A.P. Prostate cancer epidemiology. Front Biosci 1 (2006) 1388-1413
7. Stanford J.L., Noonan E.A., Kolb L.I.S., Chadwick R.B., Feng Z., and Ostrander E.A. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomark & Prev 11 (2002) 243-247
8. Niino M., Kikuchi S., Fukazawa T., Yabe I., and Tashira K. Estrogen receptor gene polymorphism in Japanese patients with multiple sclerosis. J Neurol Sci 179 (2000) 70-75
9. Massart F., Becherini L., Gennari L., Facchini V., Genazzani A.R., and Brandi M.L. Genotype distribution of estrogen receptor alpha gene polymorphisms in Italian women with surgical uterine leiomyomas. Fert Steril 75 (2001) 567-570
10. Kikuchi S., Fukazawa T., Niino M., Yabe I., Miyagishi R., Hamada T., and Tashiro K. Estrogen receptor gene polymorphism and multiple sclerosis in japanesse patients: interaction with HLA-DRB1 and disease modulation. J. Neuroimmunol 128 (2002) 77-81
11. Yamada Y., Ando F., Niino N., Ohta S., and Shimokata H. Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density of the femoral neck in elderly Japanese women. J Mol Med 80 (2002) 452-460
12. Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bachvarov D., Leblanc G., Durocher F., and Paquet N. Structure of human type II 5 alpha-reductase gene. Endocrinology 131 (1992) 1571-1573
13. Vichis F., Mendez J.P., Canto P., Lieberman E., and Chavez B. Identification of missense mutations in the SRD5A2 gene from patients with steroid 5a-reductase 2 deficiency. Clin Endocrinol 52 (2000) 383-387
14. Rao A., and Cramer S.D. Identification of a polymorphism in the ARE 1 region of the PSA promotor. Cancer Res 40 (1999) 60
15. Xue W., Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A., and Ingles S.A. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate specific antigen loci. Cancer Res. 60 (2000) 839-841
16. Sobti R.C., Onsory K., Al-Badran A.I., Kaur P., Watanabe M., Krishan A., and Mohan H. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol. 25 (2006) 287-294
17. Lunn R.M., Bell D.A., Mohler J.L., and Taylor J.A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20 (1999) 1727-1731
18. Sambrook J., Fritsch E.F., and Maniatis T. Molecular Cloning: A Laboratory Manual (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
19. Modugno F., Weissfeld J.L., Trump D.L., Zmuda J.M., Shea P., Cauley J.A., and Ferrell R.E. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7 (2001) 3092-3096
20. Yang C., Hamajima N., Iwata H., Saito T., Matsuo K., Hirose K., Inoue M., Takezaki T., and TajimaA49T K. V89L and TA repeat polymorphisms of steroid 5a-reductase type II and breast cancer risk in Japanese women. Breast Cancer Res 4 (2002) R8
21. Allen N.E., Forrest M.S., and Key T.J. The association between polymorphisms in the CYP17 and 5-alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 10 (2001) 185-189
22. Xu J., Zheng S.L., Carpten J.D., Nupponen N.N., Robbins C.M., Mestre J., Moses T.Y., Faith D.A., Kelly B.D., Isaacs S.D., Wiley K.E., Ewing C.M., Bujnovszky P., Bao-li C., Bailey-Wilson J.E.R., Walsh P.C., Trent J.M., Meyers D.A., and Isaacs W.B. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 68 (2001) 901-911
23. Suzuki K., Matsui H., Nakazato H., Koike H., Okugi H., Hasumi M., Ohtake N., Nakata S., Takei T., Hatori M., Ito K., and Yamanaka H. Association of the genetic polymorphism in cytochrome P450 CYP1A1 with risk of familial prostate cancer in a Japanese population: a case-control study. Cancer Lett 195 (2003) 177-183
24. Hernandez J., Balic I., Johnson-Pais T.L., Higgins B.A., Torkko K.C., Thompson I.M., and Leach R.J. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol 175 (2006) 523-527
25. Cai Q., Shu X., Jin F., Dai Q., Wen W., Cheng J.R., Gao Y.T., and Zheng W. Genetic polymorphism in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Brest Cancer Study. Cancer Epidemiol Biomark Prev 12 (2003) 853-859
26. Weiderpass E., Persson I., Melhus H., Wedren S., Kindmark A., and Baron J.A. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis 21 (2000) 623-627
27. Hsing A.W., Chen C., Chokkalingam A.P., Gao Y.T., Dightman D.A., Nguyen H.T., Deng J., Heng J., Sesterhenn I.A., Mostofi K., Stanczyk F.Z., and Reichardt J.K.V. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population based case control study. Cancer Epidemiol Biomark Prev 10 (2001) 1077-1082
28. Salam M.T., Ursin G., Skinner E.C., Dessissa T., and Reichardt J.K. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol 23 (2005) 246-253
29. Allen N.E., Reichardt J.K.V., Nguyen H., and Key T.J. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiol Biomark Prev 12 (2003) 578-581
30. Gsur A., Bernhofer G., Hinteregger S., Haidinger G., Schatzl G., Madersbacher S., Marberger M., Vutuc C., and Micksche M. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 87 (2000) 434-437
31. Yamada Y., Watanabe M., Murata M., Yamanaka M., Kubota Y., Ito H., Katoh T., Kawamura J., Yatani R., and Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5 alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 92 (2001) 683-686
32. Wadelius M., Andersson A.O., Johansson J.E., Wadelius C., and Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 9 (1999) 635-639
33. Habuchi T., Liqing Z., Suzuki T., Sasaki R., Tsuchiya N., Tachiki H., Shimoda N., Satoh S., Sato K., Kakehi Y., Kamoto T., Ogawa O., and Kato T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 60 (2000) 5710-5713
34. Wang L.Z., Sato K., Tsuchiya N., Yu J.G., Ohyama C., Satoh S., Habuchi T., Ogawa O., and Kato T. Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett 8 202 (2003) 53-59
35. Gsur A., Preyer M., Haidinger G., Zidek T., Madersbacher S., Schatzl G., Marberger M., Vutuc C., and Micksche M. Polymorphic CAG repeats in the androgen receptor gene, prostate specific antigen polymorphism and prostate cancer risk. Carcinogenesis 23 (2002) 1647-1651
36. Xue W., Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A., and Ingles S.A. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate specific antigen loci. Cancer Res 60 (2000) 839-841
37. Beebe-Dimmer J.L., Lange L.A., Cain J.E., Lewis R.C., Ray A.M., Sarma A.V., Lange E.M., and Cooney K.A. Polymorphisms in the prostate specific antigen gene promoter do not predict serum prostate specific antigen levels in African-American men. Prostate Cancer Prostatic Dis 9 (2006) 50-55